TransThera Sciences (HKG:2617) said China's National Medical Products Administration approved a Phase 2 clinical trial of its TT-00973 tablets in combination with firmonertinib mesylate, according to a July 10 Hong Kong bourse filing.
The combination will be evaluated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR-sensitive mutations.
The multi-center, open-label study will assess the safety and efficacy of the combination therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments